论文部分内容阅读
目的研究Dermcidin(DCD)作为新的肺癌生物标志物的可行性。方法收集病理确诊肺癌的患者手术前血清、肺癌组织和癌旁组织共31例,用ELISA方法对肺癌患者和健康对照组血清中DCD浓度作比较;利用定量聚合酶链反应(quantitative polymerase chain reaction,q PCR)方法对同一患者肺癌标本和癌旁标本进行ΔCt值的比较;利用Western blot方法对同一患者肺癌标本和癌旁标本DCD的表达量进行比较;同时利用免疫组化方法对同一患者肺癌组织和癌旁组织DCD的表达程度进行比较。结果 ELISA结果发现肺癌血清中DCD浓度高于健康对照组,差异有统计学意义(P<0.05);q PCR结果显示肺癌组与癌旁组ΔCt值的差异有统计学意义(P<0.05);Western blot结果进一步表明肺癌组织中DCD的表达量高于癌旁组织,差异有统计学意义(P<0.05);免疫组化结果也发现肺癌组织中DCD表达水平高于癌旁组织,差异有统计学意义(P<0.05)。结论 DCD与肺癌密切相关,可能成为肺癌潜在的分子标志物。
Objective To study the feasibility of Dermcidin (DCD) as a new biomarker of lung cancer. Methods Thirty-one patients with pathologically diagnosed lung cancer before operation, 31 patients with lung cancer and adjacent normal tissue were collected. The serum concentrations of DCD in patients with lung cancer and healthy controls were compared by ELISA. Quantitative polymerase chain reaction q PCR) were used to compare the ΔCt values of lung cancer specimens and adjacent non-cancerous specimens in the same patient. Western blot was used to compare the expression of DCD in lung cancer specimens and adjacent non-cancerous specimens of the same patient. Meanwhile, And the degree of paracancerous tissue DCD were compared. Results The results of ELISA showed that the concentration of DCD in lung cancer serum was higher than that in healthy controls (P <0.05). Q PCR results showed that the difference of ΔCt between lung cancer group and adjacent non - cancerous group was statistically significant (P <0.05). Western blot results further showed that the expression of DCD in lung cancer tissues was higher than that in paracancerous tissues, the difference was statistically significant (P <0.05). The results of immunohistochemistry also showed that the expression of DCD in lung cancer tissues was higher than that in paracancerous tissues Significance (P <0.05). Conclusions DCD is closely related to lung cancer and may be a potential molecular marker of lung cancer.